North America Ambulatory Infusion Centers Market Size, Share & Trends Analysis Report By Therapy Type (Anti-infective Therapy, Hydration Therapy, Chemotherapy, Immunoglobulin Therapy), By Application (Oncology, Autoimmune DisordersRheumatoid ArthritisMultiple SclerosisCrohn€™s DiseasePsoriasis, Neurological Disorders, Infectious Diseases), By Country (U.S., Canada) and Forecast, 2026-2034

North America Ambulatory Infusion Centers Market Trends

Migration Toward Technology-Enabled Alternate-Site Infusion

Infusion delivery is increasingly moving toward connected, scalable outpatient networks combining electronic referrals, benefits verification, automated claims processing and advanced-practitioner models. Option Care Health reported serving more than 315,000 patients in 2025, supported by 5,000+ clinicians, approximately 90 pharmacies, 190+ locations and 750+ infusion chairs. Its network also reaches approximately 96% of insured lives through its top 10 payer relationships.

Operational automation is becoming central to capacity expansion. Option Care reported that approximately 40% of claims were processed without human intervention, more than 25 centers offered advanced-practitioner capabilities, and over 34% of nursing visits occurred in infusion suites or clinics. Pro-forma clinic visits increased by more than 25% year over year in Q4 2025, illustrating the shift toward higher-throughput ambulatory delivery.

North America Ambulatory Infusion Centers Market Drivers

Site-of-Care Migration and Expanding Specialty Therapy Volumes

Payor preference for lower-cost care settings, rising specialty-drug utilization and chronic-disease treatment are accelerating outpatient infusion utilization. Option Care generated approximately USD 4.91 billion of infusion-services revenue in 2024 versus USD 4.22 billion in 2023 and USD 3.87 billion in 2022, while total 2024 revenue approached USD 5.0 billion. Its preliminary 2025 results subsequently indicated approximately 13% revenue expansion and service to more than 315,000 patients, demonstrating substantial commercial momentum in alternate-site infusion delivery.

North America Ambulatory Infusion Centers Market Restraints

Reimbursement Complexity and Specialty-Drug Pricing Pressure

Prior authorization, benefits re-verification, drug-price changes and payer restrictions can delay treatment initiation and pressure provider economics. Option Care's 2026 outlook incorporated an estimated USD 25–35 million headwind associated with Stelara and biosimilars, while its Q1 2026 revenue of approximately USD 1.35 billion increased only 1.3% year over year. Full-year revenue expectations were lowered by approximately USD 175 million to USD 5.675–5.775 billion, illustrating the financial sensitivity of infusion providers to reimbursement and specialty-pharmaceutical changes.

North America Ambulatory Infusion Centers Market Opportunities

Network Expansion and Consolidation of Alternate-Site Care

Acquisitions and greenfield facilities are creating scalable opportunities across underserved metropolitan and regional markets. KabaFusion's May 2025 acquisition of 6 Coram locations expanded its platform to 32 specialty pharmacies, 19 ambulatory infusion suites and operations across 26 states, while maintaining licenses covering 45 states. In 2026, Soleo Health reported a nationwide portfolio of 28 specialty pharmacies and more than 30 ambulatory infusion suites and centers, demonstrating continuing investment in distributed specialty-care infrastructure.

Challenges in North America Ambulatory Infusion Centers Market

Clinical Capacity, Scheduling and Administrative Bottlenecks

Scaling infusion throughput requires synchronized nursing, pharmacy, scheduling and payer workflows. Large oncology infusion operations can handle approximately 200–225 patients daily, while concentration of appointments between 10 a.m. and 2 p.m. can create pharmacy and staffing bottlenecks. Meanwhile, providers must coordinate thousands of clinicians and hundreds of treatment chairs; Option Care alone reported 5,000+ clinicians and 750+ chairs in 2025, underscoring the operational complexity associated with maintaining utilization, medication preparation and clinical quality simultaneously.

North America Ambulatory Infusion Centers Market Segmentation

The market is segmented by therapy type, application, end-user and payor type. Within the supplied quantitative therapy dataset, anti-infective therapy dominates at approximately 28.0% of 2026 value, chemotherapy contributes approximately 23.4%, and hydration therapy represents approximately 18.6%.

By Therapy Type

Anti-infective therapy is the largest supplied subsegment, increasing from USD 5,486.61 million in 2025 to USD 6,071.48 million in 2026 and USD 13,652.75 million by 2034, representing a 10.66% CAGR.

Hydration therapy is the fastest-growing supplied therapy category at 11.25% CAGR, advancing from USD 4,030.81 million in 2026 to USD 9,457.85 million in 2034. Chemotherapy reaches USD 11,596.66 million, immunoglobulin therapy USD 5,193.80 million, biological therapy USD 3,938.72 million, enteral/parenteral nutrition USD 2,943.48 million, and other therapies USD 2,757.65 million by 2034.

By Application

Applications comprise oncology, autoimmune disorders—including rheumatoid arthritis, multiple sclerosis, Crohn's disease and psoriasis—neurological disorders, infectious diseases, gastrointestinal disorders, immune deficiencies and others. Numerical application-level revenue and CAGR values were not supplied; consequently, no unsupported application market values are assigned.

The therapy dataset nevertheless demonstrates the scale of application-linked treatment: chemotherapy totals USD 5,083.16 million in 2026, immunoglobulin therapy USD 2,268.40 million, and biological therapy USD 1,735.20 million, supporting substantial oncology, immune and chronic-disease infusion activity.

By End-User

End-users include hospital-affiliated centers, physician-office infusion centers, standalone/independent facilities and home-infusion providers with ambulatory setups. End-user-specific revenue and CAGR figures were not provided, preventing defensible ranking of the largest or fastest-growing category.

Operational evidence confirms considerable alternate-site capacity: Option Care reported 190+ U.S. locations, 750+ chairs and roughly 90 full-service pharmacies in 2025, while more than 34% of its nursing visits occurred in suites or clinics during Q4 2025.

By Payor Type

The payor structure comprises commercial insurance, Medicare, Medicaid and out-of-pocket/self-pay. Segment-specific values and CAGRs were not supplied, so quantitative dominance cannot be assigned without introducing unsupported estimates.

Commercial payer integration remains operationally significant: Option Care reported its top 10 payers were in-network and provided approximately 96% coverage of insured lives. Automation has also reached approximately 40% of claims, highlighting the importance of payer connectivity and administrative efficiency.

North America Ambulatory Infusion Centers Market Counties Outlook

U.S.

The United States accounts for approximately 70.2% of regional 2026 value at USD 15,233.35 million, up from USD 13,712.62 million in 2025. At a 11.09% CAGR, the country is projected to reach USD 35,334.19 million by 2034. Capacity is supported by large national and regional operators spanning specialty pharmacies, physician-aligned clinics, independent centers and home/ambulatory hybrid networks.

Canada

Canada represents approximately 29.8% of the regional 2026 total, reaching USD 6,466.05 million from USD 5,840.53 million in 2025. The country is forecast to attain USD 14,592.64 million in 2034, reflecting a 10.71% CAGR and contributing approximately 29.2% of the combined country-level 2034 forecast.

Top players in North America Ambulatory Infusion Centers Market

• Option Care Health
• Coram CVS / CVS Health
• UnitedHealth Group
• IVX Health
• KabaFusion
• Soleo Health
• Vital Care
• CarepathRx
• Amerita
• AIS Healthcare
• FlexCare Infusion Centers
• Fresenius
• B. Braun
• Baxter
• BioScript Solutions

Top Two Companies

• Option Care Health

A defensible percentage company market share is not disclosed by the supplied dataset and therefore is not estimated. The company nevertheless has substantial scale, reporting315,000+ patients,190+ U.S. locations, approximately90 pharmacies,750+ infusion chairsand5,000+ cliniciansin 2025. Its top10 payerrelationships cover approximately96% of insured lives, while infusion clinic visits increased more than25% year over yearin Q4 2025 on a pro-forma basis including Intramed Plus. The company acquired Intramed Plus for approximatelyUSD 117 millionin January 2025, reinforcing its alternate-site footprint.

• IVX Health

A verified percentage company market share is likewise unavailable in the supplied numerical dataset and is not fabricated. IVX remains a prominent independent outpatient infusion operator emphasizing chronic-condition therapies and metropolitan expansion. During2025, the company opened4 new Chicago centersin January, complementing5 existing locationsin that metropolitan area, and added5 Dallas-Fort Worth centersin June. These expansions illustrate its multi-site strategy and increasing exposure to payer-driven site-of-care migration. IVX's competitive positioning centers on dedicated outpatient facilities rather than hospital-based infusion departments, creating a differentiated platform for specialty biologics and injections.

Recent Developments in North America Ambulatory Infusion Centers Market

• 2026:Soleo Health acquired Realo Specialty Care Pharmacy and BluHaven Management, complementing a network of28 specialty pharmaciesand30+ ambulatory infusion suites and centers.
• 2026:Soleo Health opened a new ambulatory infusion center in Louisville, Kentucky, expanding treatment access for rare and chronic disorders.
• 2025:KabaFusion acquired6 Coram locations, expanding to32 specialty pharmaciesand19 ambulatory infusion suites across 26 states.
• 2025:IVX Health opened5 Dallas-Fort Worth centers, extending its Texas presence across Dallas, Austin, Houston and San Antonio.
• 2025:Option Care Health completed the Intramed Plus acquisition for approximatelyUSD 117 million, strengthening its Southeastern U.S. alternate-site infusion platform.

Research Methodology

The study uses 2025 as the base year, 2026 as the current year, historical assessment across 2022–2024, and forecasts through 2034. Supplied country and therapy tables serve as the mandatory quantitative foundation; percentage contributions are calculated directly from those figures. Secondary validation covers company filings, operator disclosures and industry sources, while unsupported application, end-user, payor and company-share percentages are deliberately excluded to preserve numerical integrity.